World
Brazil trial finds efficacy of Sinovac vaccine at 50.4 percent
Aljazeera
January 13, 2021 3:39 pm
An employee holds a vial containing Sinovac Biotech's vaccine against COVID-19 at the Butantan biomedical production centre in Sao Paulo. [Source: Aljazeera]
A coronavirus vaccine developed by China’s Sinovac Biotech was found to be just 50.4 percent effective at preventing symptomatic infections of COVID-19 in a Brazilian trial.
This is barely enough for regulatory approval and well below the rate announced last week.
The latest results are a substantial disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunization during the second wave of the world’s second-deadliest COVID-19 outbreak.
Article continues after advertisement
Sponsored Links
Claim Your Money Today!
Please click here to check and inform us at [email protected] to help us settle. Check List
By LICI
Extra Weekly Specials
Don't miss out on the amazing specials on offer this week at all Extra branches. Click Here to View
By Extra Supermarket
Spend and Win Postshop Shopping Vouchers
Spend $30 or more at our Postshop or eShop and be in the draw. Shop Online Here
By Post Fiji
